Review of potential predictors of anthracycline-induced cardiotoxicity from the position of disease pathogenesis-Reference-Cited by-同舟云学术

Review of potential predictors of anthracycline-induced cardiotoxicity from the position of disease pathogenesis

Published:2022-10-19 Issue:3 Volume:37 Page:19-28
ISSN:2713-265X
Container-title:The Siberian Journal of Clinical and Experimental Medicine
language:
Short-container-title:SJCEM

Author:

Kuzheleva E. A.¹^ORCID,Garganeeva A. A.¹^ORCID,Tukish O. V.¹^ORCID,Kondratiev M. Y.¹^ORCID,Vitt K. N.¹^ORCID,Chernov V. I.²^ORCID

Affiliation:

1. Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences

2. Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences

Abstract

Cardiotoxicity of anthracycline chemotherapy drugs is one of the main interdisciplinary problems in the research area of cardio-oncology. As is known, the high antitumor efficacy of anthracycline antibiotics is significantly leveled by the development of disabling and lethal heart lesions. However, the pathogenesis of toxic heart disease, as well as diagnostic criteria and markers of anthracycline-induced cardiomyopathy are not fully understood. The article provides a detailed review of potential markers of anthracycline cardiotoxicity from the position of disease pathogenesis. The scheme of pathogenetic development of anthracycline-induced cardiomyopathy is proposed in this article. The main methods of diagnostics of toxic damage of the heart that are currently used in clinical researches of domestic and foreign scientists are reviewed.

Publisher

Cardiology Research Institute

Subject

Cardiology and Cardiovascular Medicine,Public Health, Environmental and Occupational Health,Radiology, Nuclear Medicine and imaging,Medicine (miscellaneous),Internal Medicine

Reference59 articles.

1. Kaprin A.D., Starinskij V.V., Shahzadova A.O. Malignant tumors in Russia in 2019 (morbidity and mortality). Moscow: MNIOI im. P.A. Gercena − filial FGBU «NMIC radiologii» Minzdrava Rossii; 2020:252. (In Russ.).

2. Patnaik J.L., Byers T., DiGuiseppi C., Dabelea D., Denberg T.D. Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: А retrospective cohort study. Breast Cancer Res. 2011;13(3):R64. DOI: 10.1186/bcr2901.

3. Oliveira G., Al-Kindi S., Caimi P., Lazarus H. Maximizing anthracycline tolerability in hematologic malignancies: Treat to each heart’s content. Blood Reviews. 2016;30(3):169–178. DOI: 10.1016/j.blre.2015.11.001.

4. Chazova I.Ye., Tyulyandin S.A., Vitsenya M.V., Ovchinnikov A.G., Poltavskaja M.G., Giljarov M.Ju. et al. Clinical manual for diagnosis, prevention and treatment of cardiovascular complications of cancer therapy (part I). Systemic Hypertension. 2017;14(3):6−20. (In Russ.). DOI: 10.26442/2075-082X_14.3.6-20.

5. Zamorano L.J., Lancellotti P., Muñoz D.R., Aboyans V., Asteggiano R., Galderisi M. et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur. Heart J. 2016;37(36):2768−2801. DOI: 10.1093/eurheartj/ehw211.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Allelic variant 6A (rs35068180) of the MMP-3 promoter region as a predictor of cardiotoxicity after the end of adjuvant chemotherapy with doxorubicin in patients with breast cancer;Russian Journal of Cardiology;2023-10-16